---
title: "Suxuantang Pharma drops sharply intraday after 32% rally on strong Q2 results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296254648.md"
description: "Suxuantang Pharma (SXTC.US) fell over 5% in a 5-minute span after surging 32% to $4.96, following strong Q2 earnings."
datetime: "2026-08-18T16:51:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296254648.md)
  - [en](https://longbridge.com/en/news/296254648.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296254648.md)
generator: "portal-rs"
---

# Suxuantang Pharma drops sharply intraday after 32% rally on strong Q2 results

中国苏轩堂药业 (SXTC.US) 盘中触发 5 分钟内急跌超 5% 信号，该股当日盘中涨超 32%，现报**4.96 美元**。

消息面上，该公司于 08/14/2026 盘后公布强劲第二季度业绩，推动盘后股价一度上涨超 5%。此后延续涨势，8 月 18 日盘中延续此前升势至 19% 涨幅，盘中交投活跃。消息面暂无其他明确催化剂。

### Related Stocks

- [SXTC.US](https://longbridge.com/en/quote/SXTC.US.md)

## Related News & Research

- [Cramer's lightning round: Nuvation Bio 'is a pure spec'](https://longbridge.com/en/news/297966838.md)
- [How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?](https://longbridge.com/en/news/297808527.md)
- [Fake Ozempic, Medicare And A $1.1 Trillion Lilly: 10 Things Happening In Pharma](https://longbridge.com/en/news/297898693.md)
- [Takeda President, R&D Andrew Plump sells 116,191 ADS for $2.15 million](https://longbridge.com/en/news/297977753.md)
- [How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors](https://longbridge.com/en/news/297761649.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**